These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 19474056

  • 1. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC.
    Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
    [Abstract] [Full Text] [Related]

  • 2. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J, Varela A.
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [Abstract] [Full Text] [Related]

  • 3. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 4. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
    Rosano GM, Vitale C, Volterrani M.
    Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895
    [Abstract] [Full Text] [Related]

  • 5. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 6. Heart rate in coronary syndromes and heart failure.
    Orso F, Baldasseroni S, Maggioni AP.
    Prog Cardiovasc Dis; 2009 Jan; 52(1):38-45. PubMed ID: 19615492
    [Abstract] [Full Text] [Related]

  • 7. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N.
    Therapie; 2009 Jan; 64(2):111-4. PubMed ID: 19664404
    [Abstract] [Full Text] [Related]

  • 8. Heart rate control in an unselected consecutive population of outpatients with stable coronary artery disease: Analysis of the CARDIf Study Cohort.
    Vitale C, Iellamo F, Volterrani M, Lombardi M, Fini M, Banach M, Rosano GM.
    Angiology; 2010 Nov; 61(8):763-7. PubMed ID: 20462892
    [Abstract] [Full Text] [Related]

  • 9. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators.
    Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
    [Abstract] [Full Text] [Related]

  • 10. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB.
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [Abstract] [Full Text] [Related]

  • 11. [Heart rate: a cardiovascular risk factor that can no longer be ignored].
    Palatini P.
    G Ital Cardiol (Rome); 2006 Feb; 7(2):119-28. PubMed ID: 16532723
    [Abstract] [Full Text] [Related]

  • 12. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E, Lerebours G, Vilaine JP.
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [Abstract] [Full Text] [Related]

  • 13. I(f) inhibition in cardiovascular diseases.
    Thollon C, Vilaine JP.
    Adv Pharmacol; 2010 Mar; 59():53-92. PubMed ID: 20933199
    [Abstract] [Full Text] [Related]

  • 14. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.
    Diaz A, Bourassa MG, Guertin MC, Tardif JC.
    Eur Heart J; 2005 May; 26(10):967-74. PubMed ID: 15774493
    [Abstract] [Full Text] [Related]

  • 15. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
    Reil JC, Reil GH, Böhm M.
    Trends Cardiovasc Med; 2009 Jul; 19(5):152-7. PubMed ID: 20005474
    [Abstract] [Full Text] [Related]

  • 16. Resting heart rate in cardiovascular disease.
    Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M, Heart Rate Working Group.
    J Am Coll Cardiol; 2007 Aug 28; 50(9):823-30. PubMed ID: 17719466
    [Abstract] [Full Text] [Related]

  • 17. High heart rate: more than a risk factor. Lessons from a clinical practice survey.
    Barrios V, Escobar C, Bertomeu V, Murga N, de Pablo C, Asín E.
    Int J Cardiol; 2009 Nov 12; 137(3):292-4. PubMed ID: 18684521
    [Abstract] [Full Text] [Related]

  • 18. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011 Nov 12; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 19. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
    Tendera M, Talajic M, Robertson M, Tardif JC, Ferrari R, Ford I, Steg PG, Fox K, BEAUTIFUL Investigators.
    Am J Cardiol; 2011 Mar 15; 107(6):805-11. PubMed ID: 21247517
    [Abstract] [Full Text] [Related]

  • 20. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure.
    Sarullo FM, Fazio G, Puccio D, Fasullo S, Paterna S, Novo S, Di Pasquale P.
    J Cardiovasc Pharmacol Ther; 2010 Dec 15; 15(4):349-55. PubMed ID: 20940450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.